
    
      It is a clinical trial phase I, single center, non-randomized, uncontrolled, open prospective
      follow-up of a cohort of patients with chronic spinal cord injury (SCI) .10 patients will be
      included with this injury.

      Primary objective: Analyze the possible clinical efficacy of administration of main adult
      mesenchymal autologous cells expanded "in vitro" in patients with incomplete and chronically
      established SCI.

      Secondary objectives: Confirm the safety of treatment, and study possible changes in the
      cerebrospinal fluid (CSF) levels (Brain-derived neurotrophic factor (BDNF), glial cell
      line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), ciliary neurotrophic
      factor (CNTF), Nerve Growth Factor 3 and 4(NT3 and NT4) after subarachnoid administration of
      BMMC.
    
  